17.1 Demography, Fertility Rates & Family Welfare Indicators

17.1 Demography, Fertility Rates & Family Welfare Indicators

Demography is the scientific study of human populations, primarily focusing on their size, structure, development, and vital dynamics. For the UPSC Combined Medical Services (CMS) examination, a thorough understanding of demographic processes, fertility indicators, contraceptive technology, and family welfare program statistics is essential.

---

1. The Demographic Cycle and Demographic Transition

The demographic cycle describes the transformation of a population over time through changes in birth rates and death rates. It consists of five distinct stages:

Demographic Dividend

India is currently experiencing a window of Demographic Dividend, defined as the economic growth potential that results from shifts in a population's age structure, specifically when the proportion of the working-age population (15–64 years) is larger than the non-working-age dependent population (<15 years and ≥65 years).

---

2. Demographic Indicators and Formulas

Public health specialists use specific quantitative indicators to analyze fertility, mortality, and population structure.

A. Fertility Indicators

1. Crude Birth Rate (CBR):

   $$\text{CBR} = \frac{\text{Total number of live births during a given year}}{\text{Mid-year total population}} \times 1000$$

   Note: Called "crude" because the denominator includes the entire population (males, children, elderly) rather than just females of reproductive age.

2. General Fertility Rate (GFR):

   $$\text{GFR} = \frac{\text{Total number of live births in a year}}{\text{Mid-year female population aged 15--49 years}} \times 1000$$

   Significance: Better indicator than CBR as it restricts the denominator to women of childbearing age (15–49 years).

3. General Marital Fertility Rate (GMFR):

   $$\text{GMFR} = \frac{\text{Total number of live births in a year}}{\text{Mid-year married female population aged 15--49 years}} \times 1000$$

4. Age-Specific Fertility Rate (ASFR):

   $$\text{ASFR} = \frac{\text{Live births to women in a specific age group in a year}}{\text{Mid-year female population of that specific age group}} \times 1000$$

   Clinical Note: In India, peak fertility is observed in the 20–24 years age group, followed by the 25–29 years group.

5. Total Fertility Rate (TFR):

   $$\text{TFR} = 5 \times \sum_{i=1}^{7} \text{ASFR}_i \div 1000$$

   Definition: The average number of children that would be born alive to a woman during her lifetime if she were to pass through her childbearing years conforming to the age-specific fertility rates of a given year.

   • Replacement Level TFR: 2.1 (The extra 0.1 accounts for female mortality before reaching reproductive age and sex ratio imbalances).
   • National Status (NFHS-5, 2019-21): India's TFR has declined to 2.0 nationally (Urban: 1.6, Rural: 2.1), reaching below replacement level.

6. Gross Reproduction Rate (GRR): Definition: Average number of daughters that would be born to a woman if she passed through her reproductive years assuming current age-specific fertility rates, without accounting for female mortality.

7. Net Reproduction Rate (NRR): Definition: Average number of daughters that would be born to a female child if she passed through her lifetime conforming to current age-specific fertility and mortality rates.

   • NRR = 1: Indicates that each generation of mothers is exactly replacing itself (Replacement level).
   • Target Relationship: NRR = 1 corresponds to a Total Fertility Rate of 2.1 and a Couple Protection Rate (CPR) of ~60%.

B. Structural and Dependency Indicators

1. Sex Ratio: In India, defined as the number of females per 1,000 males. (NFHS-5 overall sex ratio: 1,020 females per 1,000 males; Sex Ratio at Birth: 929 per 1,000 males).
2. Child Sex Ratio: Number of females per 1,000 males in the 0–6 years age group.
3. Dependency Ratio: $$\text{Dependency Ratio} = \frac{\text{Population (0--14 yrs)} + \text{Population (}\ge 65\text{ yrs)}}{\text{Population (15--64 yrs)}} \times 100$$
   • Child Dependency Ratio: $\frac{\text{Pop (0--14)}}{\text{Pop (15--64)}} \times 100$
   • Aged Dependency Ratio: $\frac{\text{Pop (}\ge 65\text{)}}{\text{Pop (15--64)}} \times 100$

---

3. Contraceptive Technology and Family Welfare Methods

Contraceptive methods are divided into Temporary (Spacing) and Permanent (Terminal) methods.

A. Temporary (Spacing) Contraceptive Methods

1. Barrier Methods

• Male Condom (Nirodh): Latex sheath. Provides dual protection: contraception and protection against Sexually Transmitted Infections (STIs)/HIV. Ideal for spacing and early marital life.
• Female Condom (FC2): Polyurethane/nitrile sheath with two rings.
• Diaphragm & Cervical Cap: Vaginal barrier used with spermicidal jelly (Nonoxynol-9). Must be kept in place for at least 6 hours post-coitus.

2. Intrauterine Contraceptive Devices (IUCDs)

• First Generation: Non-medicated IUCDs (e.g., Lippes Loop). Made of polyethylene with barium sulfate. Causes mild sterile endometrial inflammatory reaction.
• Second Generation (Copper IUCDs):
  • CuT-380A: Surface area of copper is 380 mm². Lifespan: 10 years. Approved for postpartum placement (within 48 hours) or interval placement.
  • CuT-375: Lifespan: 5 years.
  • Mechanism of action: Copper ions exert spermicidal action by inhibiting sperm motility, viability, and acrosomal reaction; alters endometrial environment.
• Third Generation (Hormone-Releasing IUCDs):
  • Levonorgestrel-releasing IUD (LNG-20 / Mirena): Releases 20 mcg of levonorgestrel per day. Lifespan: 5 to 8 years.
  • Mechanism: Cervical mucus thickening (blocks sperm entry), endometrial atrophy (prevents implantation).
  • Therapeutic Indication: Highly effective treatment for Idiopathic Heavy Menstrual Bleeding (Menorrhagia) and Endometriosis.
• Side Effects & Complications of IUCDs:
  • Most common symptom/side effect: Bleeding and Pain (most common reason for removal).
  • Most dangerous complication: Uterine Perforation (highest risk during immediate postpartum insertion or un-experienced hands, incidence ~1 in 1000 insertions).
  • Infection: Pelvic Inflammatory Disease (PID) risk is highest in the first 20 days post-insertion (Actinomyces israelii association).
  • Expulsion: Most common in the first few months, especially during menstruation.

3. Hormonal Contraception

• Combined Oral Contraceptive Pills (COCPs):

  • Composition under Government of India (Mala-N / Mala-D): Ethinylestradiol (30 mcg) + Levonorgestrel (0.15 mg).
  • Regimen: 21 active hormonal pills + 7 iron pills (Ferrous Fumarate 60 mg elemental iron) taken daily starting on Day 1 to Day 5 of the menstrual cycle.
  • Mechanism of Action: Primary mechanism is inhibition of ovulation by suppressing LH surge via negative feedback on the hypothalamus-pituitary axis. Secondary mechanisms: cervical mucus thickening and endometrial alteration.
  • Non-contraceptive benefits: Reduces risk of Ovarian Cancer and Endometrial Cancer (protective effect persists for years after stopping), reduces benign breast disease, dysmenorrhea, PID, and ectopic pregnancy.
  • Absolute Contraindications:
    1. History of Venous Thromboembolism (DVT/PE) or thrombophilic disorders.
    2. Ischemic heart disease, stroke, or severe hypertension (BP ≥160/100 mmHg).
    3. Active liver disease, cirrhosis, or hepatocellular carcinoma.
    4. Breast cancer (current or recent past).
    5. Smokers aged >35 years who smoke ≥15 cigarettes/day.
    6. Migraine with aura.

• Centchroman / Ormeloxifene (Saheli / Chhaya):

  • Non-hormonal, non-steroidal Selective Estrogen Receptor Modulator (SERM). Developed by Central Drug Research Institute (CDRI, Lucknow).
  • Dosage Regimen: Twice weekly for the first 3 months, followed by once weekly thereafter (e.g., Sunday and Wednesday for 3 months, then every Sunday).
  • Mechanism: Prevents implantation by creating asynchronous endometrial development and altering tubal motility. Ovulation is not suppressed.
  • Side Effect: Delayed menstruation (scanty or delayed periods in ~8-10% of users).

• Injectable Contraceptives (Antara Program):

  • Depot Medroxyprogesterone Acetate (DMPA): Dose 150 mg Deep IM every 3 months (12 weeks).
  • Mechanism: Suppresses LH surge, inhibiting ovulation; thickens cervical mucus.
  • Side Effects: Irregular bleeding, spotting, eventual amenorrhea (common after 1 year of use), slight delay in return of fertility (6–9 months), mild drop in bone mineral density.

• Emergency Contraception:

  • Levonorgestrel (LNG 1.5 mg single dose): Must be taken as soon as possible within 72 hours of unprotected coitus. Suppresses or delays ovulation. Ineffective after implantation has occurred.
  • Ulipristal Acetate (30 mg single dose): Selective progesterone receptor modulator effective up to 120 hours (5 days).
  • Copper T 380A: Most effective emergency contraceptive; inserted within 5 days of unprotected coitus (failure rate <0.1%).

B. Permanent (Terminal) Contraceptive Methods

1. Female Sterilization (Tubal Ligation)

• Techniques: Modified Pomeroy's technique (minilaparotomy) or Laparoscopic tubal occlusion using Falope rings / Filshie clips.
• Timing: Postpartum (within 7 days, ideally 24–48 hours post-delivery) or Interval (after 6 weeks post-delivery).

2. Male Sterilization (Non-Scalpel Vasectomy - NSV)

• Technique: Puncture technique developed by Li Shunqiang; vas deferens is isolated, ligated, and occluded without skin incision.
• Post-Procedure Criteria for Sterility: The male is not immediately sterile. Must use alternative contraception (e.g., condoms) for at least 3 months or until 2 consecutive semen analyses confirm azoospermia (or ~30 ejaculations).

---

4. Evaluation of Contraceptive Efficacy: Pearl Index

The efficacy of a contraceptive method is evaluated using the Pearl Index:

$$\text{Pearl Index} = \frac{\text{Total number of accidental pregnancies}}{\text{Total months of exposure (or woman-months of use)}} \times 1200$$

Note: The factor 1200 converts woman-months of use into 100 woman-years of exposure (since 100 women × 12 months = 1,200 months).

• Interpretation: Represents the number of failure pregnancies per 100 woman-years of use. A lower Pearl Index indicates a more effective contraceptive method.
• Typical Pearl Index values:
  • Implants (Nexplanon): ~0.05
  • Vasectomy: ~0.15
  • LNG-20 IUD / CuT-380A: ~0.2–0.8
  • Combined Oral Pills (typical use): ~3–7
  • Condoms (typical use): ~12–13
  • Natural / Rhythm Method: ~20–24